Figure 2From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study Patient and physician-reported treatment benefit after switching from tolterodine ER to fesoterodine. CGI-I, Global Improvement subscale; TBS, Treatment Benefit Scale.Back to article page